Mar 27, 2024 Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
Mar 25, 2024 Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial
Mar 20, 2024 Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024
Dec 19, 2023 Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants
Dec 6, 2023 Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine